

L Number	Hits	Search Text	DB	Time stamp
1	1971	((544/277,278,279) or (514/260.1,263.22,263.37,264.11)).CCLS.	USPAT; US-PGPUB	2004/08/28 11:58
2	1	(((544/277,278,279) or (514/260.1,263.22,263.37,264.11)).CCLS.) and amine NEAR35 pyrazol NEAR10 "3-yl"	USPAT; US-PGPUB	2004/08/28 11:59
3	13	(((544/277,278,279) or (514/260.1,263.22,263.37,264.11)).CCLS.) and amine NEAR35 pyrazol	USPAT; US-PGPUB	2004/08/28 12:00

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal61ltxm

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1	Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	"Ask CAS" for self-help around the clock
NEWS	3	May 12 EXTEND option available in structure searching
NEWS	4	May 12 Polymer links for the POLYLINK command completed in REGISTRY
NEWS	5	May 27 New UPM (Update Code Maximum) field for more efficient patent SDIs in CApplus
NEWS	6	May 27 CApplus super roles and document types searchable in REGISTRY
NEWS	7	Jun 28 Additional enzyme-catalyzed reactions added to CASREACT
NEWS	8	Jun 28 ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R)
NEWS	9	Jul 12 BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS	10	Jul 30 BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting
NEWS	11	AUG 02 IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS	12	AUG 02 CApplus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS	13	AUG 02 STN User Update to be held August 22 in conjunction with the 228th ACS National Meeting
NEWS	14	AUG 02 The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS	15	AUG 04 Pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! will change September 1, 2004
NEWS	16	AUG 27 BIOCOMMERCE: Changes and enhancements to content coverage
NEWS	17	AUG 27 BIOTECHABS/BIOTECHDS: Two new display fields added for legal status data from INPADOC
NEWS EXPRESS	JULY 30	CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS INTER		General Internet Information
NEWS LOGIN		Welcome Banner and News Items
NEWS PHONE		Direct Dial and Telecommunication Network Access to STN
NEWS WWW		CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:01:16 ON 28 AUG 2004

=> file reg

FILE 'REGISTRY' ENTERED AT 11:01:27 ON 28 AUG 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 AUG 2004 HIGHEST RN 733665-25-3

DICTIONARY FILE UPDATES: 26 AUG 2004 HIGHEST RN 733665-25-3

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10624800.str



chain nodes :

12 13

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 15 16 17 18

chain bonds :

4-12 6-13 7-12

ring bonds :

1-2 1-6 2-3 2-15 3-4 3-18 4-5 5-6 7-8 7-11 8-9 9-10 10-11 15-16 16-17 17-18

exact/norm bonds :
 4-12 6-13 7-8 7-11 7-12 8-9 9-10 10-11
 normalized bonds :
 1-2 1-6 2-3 2-15 3-4 3-18 4-5 5-6 15-16 16-17 17-18
 isolated ring systems :
 containing 1 : 7 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 11:Atom 12:CLASS 13:Atom 15:Atom 16:Atom 17:Atom 18:Atom

L1 STRUCTURE UPLOADED

=> s l1

SAMPLE SEARCH INITIATED 11:02:10 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 95 TO ITERATE

100.0% PROCESSED 95 ITERATIONS
 SEARCH TIME: 00.00.01



8 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 1316 TO 2484
 PROJECTED ANSWERS: 8 TO 329

L2 8 SEA SSS SAM L1

=>

Uploading C:\Program Files\Stnexp\Queries\10624800.str



chain nodes :

12 13

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 15 16 17 18

chain bonds :

4-12 6-13 7-12

ring bonds :

1-2 1-6 2-3 2-15 3-4 3-18 4-5 5-6 7-8 7-11 8-9 9-10 10-11 15-16 16-17
 17-18

09/624,800

Thomas McKenzie

exact/norm bonds :
4-12 6-13 7-8 7-11 7-12 8-9 9-10 10-11
normalized bonds :
1-2 1-6 2-3 2-15 3-4 3-18 4-5 5-6 15-16 16-17 17-18
isolated ring systems :
containing 1 : 7 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:Atom 15:Atom 16:Atom 17:Atom 18:Atom

L3 STRUCTURE UPLOADED

=> s l3 subset = l2 sample
SAMPLE SUBSET SEARCH INITIATED 11:03:10 FILE 'REGISTRY'
SAMPLE SUBSET SCREEN SEARCH COMPLETED - 8 TO ITERATE

100.0% PROCESSED 8 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET):	ONLINE	**COMPLETE**	
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):	8 TO		329
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):	1 TO		80

L4 1 SEA SUB=L2 SSS SAM L3

=> s l1 full
FULL SEARCH INITIATED 11:03:38 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1933 TO ITERATE

100.0% PROCESSED 1933 ITERATIONS 205 ANSWERS
SEARCH TIME: 00.00.01

L5 205 SEA SSS FUL L1

=> s l3 subset = l5 full
FULL SUBSET SEARCH INITIATED 11:03:49 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 205 TO ITERATE

100.0% PROCESSED 205 ITERATIONS 33 ANSWERS
SEARCH TIME: 00.00.01

L6 33 SEA SUB=L5 SSS FUL L3

=> s l5 not l6
L7 172 L5 NOT L6

=> file caplus, caold; s l7
FILE 'CAPLUS' ENTERED AT 11:06:30 ON 28 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CAOLD' ENTERED AT 11:06:30 ON 28 AUG 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

L8 16 L7

=> s WO-200200057259/pn

L9 1 WO-200200057259/PN

=> s l8 not l9

L10 15 L8 NOT L9

=> sort py l10

SORT ENTIRE ANSWER SET? (Y)/N:.

PROCESSING COMPLETED FOR L10

L11 15 SORT L10 PY

=> d 1-15 cbib pi hitstr

L11 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN

2002:849586 Document No. 137:370099 Preparation of 3-aminopyrazolo[3,4-c]pyridazines as inhibitors of glycogen synthase kinase-3 and crystal structures of gsk-3 β protein and protein complexes. Ter Haar, Ernst; Swenson, Lovorka; Green, Jeremy; Arnost, Michael J. (Vertex Pharmaceuticals Incorporated, USA). PCT Int. Appl. WO 2002088078 A2 20021107, 778 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2002-US13511 20020429. PRIORITY: US 2001-PV287366 20010430; US 2001-PV297094 20010608; US 2002-PV361899 20020227.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002088078	A2	20021107	WO 2002-US13511	20020429
WO 2002088078	A3	20040506		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003125332	A1	20030703	US 2002-135255	20020429
EP 1435957	A2	20040714	EP 2002-729056	20020429
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			

IT 474381-74-3P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)

(crystal structure determination; preparation of pyrazolopyridazines as inhibitors

of gsk-3 and crystal structures of gsk-3 β protein and protein complexes)

RN 474381-74-3 CAPLUS

CN Kinase (phosphorylating), glycogen synthetase (human isoenzyme 3 β),
compd. with N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-4-quinazolinamine
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 474231-10-2

CMF Unspecified


CCI MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 404828-10-0

CMF C17 H14 N6



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L11 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN

2002:845560 Document No. 137:353051 Preparation of quinazolines as
TGF- β and/or p38- α kinase inhibitors. Chakravarty, Sarvajit;
Dugar, Sundeep; Perumattam, John J.; Schreiner, George F.; Liu, David Y.;
Lewicki, John A. (Scios, Inc., USA). U.S. US 6476031 B1 20021105, 37 pp.,
Cont.-in-part of U.S. 6,184,226. (English). CODEN: USXXAM. APPLICATION:
US 1999-383825 19990827. PRIORITY: US 1998-141916 19980828.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6476031	B1	20021105	US 1999-383825	19990827
	US 6184226	B1	20010206	US 1998-141916	19980828
	US 6277989	B1	20010821	US 2000-525034	20000314
	US 2003069248	A1	20030410	US 2001-969936	20011002
	US 2002161010	A1	20021031	US 2001-972582	20011005


IT **404828-44-0P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(drug candidate; preparation of quinazolines as TGF- β and/or p38- α kinase inhibitors)

RN 404828-44-0 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazol-3-yl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L11 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN


2002:615605 Document No. 137:169539 Preparation of 3-(4-pyrimidinylamino)-1H-pyrazoles as protein kinase inhibitors, especially of Aurora-2 and GSK-3, for treatment of cancer, diabetes, and Alzheimer's disease. Bebbington, David; Charrier, Jean-Damien; Golec, Julian M. C.; Miller, Andrew; Knegt, Ronald (Vertex Pharmaceuticals Incorporated, USA). PCT Int. Appl. WO 2002062789 A1 20020815, 335 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US51031 20011219.

PRIORITY: US 2000-PV257887 20001221; US 2001-PV286949 20010427.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI	WO 2002062789	A1	20020815	WO 2001-US51031	20011219
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
	WO 2002066461	A1	20020829	WO 2001-US49139	20011219
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,	

CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 WO 2002068415 A1 20020906 WO 2001-US50312 20011219
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
 PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
 US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 US 2003004161 A1 20030102 US 2001-26975 20011219
 US 6653300 B2 20031125
 US 2003036543 A1 20030220 US 2001-25164 20011219
 US 6664247 B2 20031216
 US 2003055068 A1 20030320 US 2001-26967 20011219
 US 2003078275 A1 20030424 US 2001-27001 20011219
 US 6653301 B2 20031125
 US 2003105090 A1 20030605 US 2001-26966 20011219
 EP 1345922 A1 20030924 EP 2001-271061 20011219
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 EP 1345927 A1 20030924 EP 2001-994510 20011219
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 EP 1355905 A1 20031029 EP 2001-273861 20011219
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 NZ 526472 A 20040430 NZ 2001-526472 20011219
 JP 2004518703 T2 20040624 JP 2002-563142 20011219
 JP 2004518743 T2 20040624 JP 2002-565976 20011219
 JP 2004519479 T2 20040702 JP 2002-567928 20011219
 US 2003004164 A1 20030102 US 2001-34683 20011220
 US 6656939 B2 20031202
 US 2003022885 A1 20030130 US 2001-34019 20011220
 US 6727251 B2 20040427
 NO 2003002704 A 20030821 NO 2003-2704 20030613
 NO 2003002736 A 20030818 NO 2003-2736 20030616
 US 2004116454 A1 20040617 US 2003-692355 20031023
 US 2004157893 A1 20040812 US 2003-722374 20031125
 US 2004132781 A1 20040708 US 2003-736426 20031215
 US 2004167141 A1 20040826 US 2004-775699 20040210
 IT **438206-29-2P**, (5-Methyl-1H-pyrazol-3-yl)[2-(2-
 phenylcyclopropyl)quinazolin-4-yl]amine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (protein kinase inhibitor; preparation of (pyrimidinylamino)pyrazoles as
 protein kinase inhibitors for treatment of cancer, diabetes, and
 Alzheimer's disease)
 RN **438206-29-2** CAPLUS
 CN **4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(2-phenylcyclopropyl)-**
 (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L11 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN
 2002:575069 Document No. 137:109292 Preparation of 3-(4-pyrimidinylamino)-1H-pyrazoles as protein kinase inhibitors, especially of Aurora-2 and GSK-3, for treatment of cancer, diabetes, and Alzheimer's disease. Bebbington, David; Charrier, Jean-Damien; Davies, Robert; Golec, Julian; Kay, David; Knegetel, Ronald; Patel, Sanjay (Vertex Pharmaceuticals Incorporated, USA). PCT Int. Appl. WO 2002059111 A2 20020801, 337 pp.
 DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US51120 20011219. PRIORITY: US 2000-PV257887 20001221; US 2001-PV286949 20010427.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002059111	A2	20020801	WO 2001-US51120	20011219
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2002066461	A1	20020829	WO 2001-US49139	20011219
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2002068415	A1	20020906	WO 2001-US50312	20011219
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,			

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
 PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
 US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003004161	A1	20030102	US 2001-26975	20011219
US 6653300	B2	20031125		
US 2003036543	A1	20030220	US 2001-25164	20011219
US 6664247	B2	20031216		
US 2003055068	A1	20030320	US 2001-26967	20011219
US 2003078275	A1	20030424	US 2001-27001	20011219
US 6653301	B2	20031125		
US 2003105090	A1	20030605	US 2001-26966	20011219
EP 1345922	A1	20030924	EP 2001-271061	20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1345926	A2	20030924	EP 2001-993360	20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001016493	A	20030930	BR 2001-16493	20011219
EP 1355905	A1	20031029	EP 2001-273861	20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 526468	A	20040326	NZ 2001-526468	20011219
NZ 526472	A	20040430	NZ 2001-526472	20011219
JP 2004517926	T2	20040617	JP 2002-559413	20011219
JP 2004518743	T2	20040624	JP 2002-565976	20011219
JP 2004519479	T2	20040702	JP 2002-567928	20011219
US 2003004164	A1	20030102	US 2001-34683	20011220
US 6656939	B2	20031202		
US 2003022885	A1	20030130	US 2001-34019	20011220
US 6727251	B2	20040427		
NO 2003002670	A	20030815	NO 2003-2670	20030612
NO 2003002704	A	20030821	NO 2003-2704	20030613
US 2004116454	A1	20040617	US 2003-692355	20031023
US 2004157893	A1	20040812	US 2003-722374	20031125
US 2004132781	A1	20040708	US 2003-736426	20031215
US 2004167141	A1	20040826	US 2004-775699	20040210


IT 438206-29-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(protein kinase inhibitor; preparation of (pyrimidinylamino)pyrazoles as
 protein kinase inhibitors for treatment of cancer, diabetes, and
 Alzheimer's disease)

RN 438206-29-2 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(2-phenylcyclopropyl)-
 (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L11 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN


2002:487556 Document No. 137:47221 Preparation of 3-(4-pyrimidinylamino)-1H-pyrazoles as protein kinase inhibitors, especially of Aurora-2 and GSK-3, for treatment of cancer, diabetes, and Alzheimer's disease.

Bebbington, David; Charrier, Jean-Damien; Davies, Robert; Everitt, Simon; Kay, David; Knegt, Ronald; Patel, Sanjay (Vertex Pharmaceuticals Incorporated, USA). PCT Int. Appl. WO 2002050065 A2 20020627, 342 pp.

DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US49140 20011219. PRIORITY: US 2000-PV257887 20001221; US 2001-PV286949 20010427.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002050065	A2	20020627	WO 2001-US49140	20011219
WO 2002050065	A3	20021024		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002034047	A5	20020701	AU 2002-34047	20011219
WO 2002066461	A1	20020829	WO 2001-US49139	20011219
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

WO 2002068415	A1	20020906	WO 2001-US50312	20011219
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003004161	A1	20030102	US 2001-26975	20011219
US 6653300	B2	20031125		
US 2003036543	A1	20030220	US 2001-25164	20011219
US 6664247	B2	20031216		
US 2003055068	A1	20030320	US 2001-26967	20011219
US 2003078275	A1	20030424	US 2001-27001	20011219
US 6653301	B2	20031125		
US 2003105090	A1	20030605	US 2001-26966	20011219
EP 1345922	A1	20030924	EP 2001-271061	20011219
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
EP 1345925	A2	20030924	EP 2001-985059	20011219
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
EP 1355905	A1	20031029	EP 2001-273861	20011219
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
NZ 526472	A	20040430	NZ 2001-526472	20011219
JP 2004516291	T2	20040603	JP 2002-551561	20011219
JP 2004518743	T2	20040624	JP 2002-565976	20011219
JP 2004519479	T2	20040702	JP 2002-567928	20011219
US 2003004164	A1	20030102	US 2001-34683	20011220
US 6656939	B2	20031202		
US 2003022885	A1	20030130	US 2001-34019	20011220
US 6727251	B2	20040427		
NO 2003002671	A	20030818	NO 2003-2671	20030612
NO 2003002704	A	20030821	NO 2003-2704	20030613
US 2004116454	A1	20040617	US 2003-692355	20031023
US 2004157893	A1	20040812	US 2003-722374	20031125
US 2004132781	A1	20040708	US 2003-736426	20031215
US 2004167141	A1	20040826	US 2004-775699	20040210
IT 438206-29-2P,	(5-Methyl-1H-pyrazol-3-yl)[2-(2-phenylcyclopropyl)quinazolin-4-yl]amine			
RL:	PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)			
	(protein kinase inhibitor; preparation of (pyrimidinylamino)pyrazoles as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)			
RN 438206-29-2	CAPLUS			
CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(2-phenylcyclopropyl)-(9CI)	(CA INDEX NAME)			



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L11 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN

2002:220584 Document No. 136:247584 Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease. Bebbington, David; Knegtel, Ronald; Golec, Julian M. C.; Li, Pan; Davies, Robert; Charrier, Jean-Damien (Vertex Pharmaceuticals Incorporated, USA). PCT Int. Appl. WO 2002022608 A1 20020321, 356 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US42152 20010914. PRIORITY: US 2000-PV232795 20000915; US 2000-PV257887 20001221; US 2001-PV286949 20010427.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002022608	A1	20020321	WO 2001-US42152	20010914
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001096871	A5	20020326	AU 2001-96871	20010914
US 2003055044	A1	20030320	US 2001-953505	20010914
US 6638926	B2	20031028		
US 2003064981	A1	20030403	US 2001-952836	20010914
US 6613776	B2	20030902		
US 2003064982	A1	20030403	US 2001-952875	20010914
US 2003073687	A1	20030417	US 2001-952671	20010914
US 6660731	B2	20031209		
US 2003078166	A1	20030424	US 2001-955601	20010914
US 6696452	B2	20040224		
US 2003083327	A1	20030501	US 2001-952833	20010914
US 6610677	B2	20030826		
EP 1317452	A1	20030611	EP 2001-977779	20010914

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2004509118 T2 20040325 JP 2002-526861 20010914
US 2004097501 A1 20040520 US 2001-953471 20010914
EP 1345922 A1 20030924 EP 2001-271061 20011219

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

EP 1355905 A1 20031029 EP 2001-273861 20011219


R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

NZ 526472 A 20040430 NZ 2001-526472 20011219
JP 2004518743 T2 20040624 JP 2002-565976 20011219
JP 2004519479 T2 20040702 JP 2002-567928 20011219
NO 2003001188 A 20030513 NO 2003-1188 20030314
NO 2003002704 A 20030821 NO 2003-2704 20030613
US 2004116454 A1 20040617 US 2003-692355 20031023
US 2004157893 A1 20040812 US 2003-722374 20031125
US 2004132781 A1 20040708 US 2003-736426 20031215
US 2004167141 A1 20040826 US 2004-775699 20040210

IT **404826-20-6P**, [2-(3,4-Dichlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404826-21-7P**, [2-(4-Bromophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404826-22-8P**, (2-Biphenyl-4-ylquinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine **404826-23-9P**, [2-(4-Ethynylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-54-2P**, (5-Methoxycarbonyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-58-6P**, (5-Benzyloxypropyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-61-1P**, [5-(3-tert-Butoxycarbonylaminopropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404829-04-5P**, (5-Methoxycarbonyl-2H-pyrazol-3-yl) [2-(piperidine-1-yl)quinazolin-4-yl]amine

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(protein kinase inhibitor; preparation of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)


RN 404826-20-6 CAPLUS
CN 4-Quinazolinamine, 2-(3,4-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-21-7 CAPLUS


CN 4-Quinazolinamine, 2-(4-bromophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-22-8 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-4-yl-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-23-9 CAPLUS


CN 4-Quinazolinamine, 2-(4-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404828-54-2 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 404828-58-6 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-[5-[3-(phenylmethoxy)propyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404828-61-1 CAPLUS

CN Carbamic acid, [3-[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 404829-04-5 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[[2-(1-piperidinyl)-4-quinazolinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



IT **404826-60-4P**, (5-Methyl-2H-pyrazol-3-yl)[2-(2-methylphenyl)quinazolin-4-yl]amine **404826-61-5P**, [2-(2,4-Difluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404826-62-6P**, [2-(2,5-Dimethoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404826-63-7P**, [2-(2-Chlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404826-64-8P**, [2-(2-Methoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404826-65-9P**, [2-(2,6-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404826-66-0P**, [2-(2-Acetylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404826-67-1P**, [2-(2,3-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404826-68-2P**, (5-Methyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-69-3P**, [2-(2-Ethylphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine **404826-70-6P**, (2-Biphenyl-2-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404826-71-7P**, [2-(2-Hydroxyphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine **404826-72-8P**, [2-(2-Ethoxyphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine **404826-73-9P**, [5-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-74-0P**, [4-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-75-1P**, (4-Phenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-76-2P**, (5-tert-Butyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-77-3P**, (5-Phenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-78-4P**, (4,5-Diphenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-79-5P**, (4-Carbamoyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-80-8P**, (2H-Pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-81-9P**, (5-Hydroxy-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-82-0P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-83-1P**, (5-Methoxymethyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-35-6P**, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404827-56-1P**, (5-Methyl-2H-pyrazol-3-yl)[2-(2-naphthyl-1-yl)quinazolin-4-yl]amine **404828-08-6P**, (5-Methyl-2H-pyrazol-3-yl)(2-phenyl-5,6,7,8-tetrahydroquinazolin-4-yl)amine **404828-09-7P**

, (5-Methyl-2H-pyrazol-3-yl) (2-phenyl-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl) amine **404828-10-0P**,
(5-Methyl-2H-pyrazol-3-yl) (2-pyridin-4-ylquinazolin-4-yl) amine **404828-11-1P**, (7-Chloro-2-pyridin-4-ylquinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl) amine **404828-12-2P**, (6-Chloro-2-pyridin-4-ylquinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl) amine **404828-13-3P**, (2-Cyclohexylquinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl) amine **404828-14-4P**, (5-Methyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl) amine **404828-15-5P**, [2-(4-Iodophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl) amine **404828-16-6P**, [2-(4-Chlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl) amine **404828-17-7P**, [2-(3,5-Dichlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl) amine **404828-18-8P**, [2-(4-Cyanophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl) amine **404828-19-9P**, [2-(3-Iodophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl) amine **404828-20-2P**, [2-(4-Ethylsulfanylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl) amine **404828-21-3P**, (5-Cyclopropyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl) amine **404828-22-4P**, [2-(4-tert-Butylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl) amine **404828-23-5P**, [2-(4-Chlorophenyl)quinazolin-4-yl] (5-cyclopropyl-2H-pyrazol-3-yl) amine **404828-24-6P**, (2-Benzo[1,3]dioxol-5-ylquinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl) amine **404828-25-7P**, [2-(4-Dimethylaminophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl) amine **404828-26-8P**, [2-(3-Methoxyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl) amine **404828-27-9P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dichlorophenyl)quinazolin-4-yl] amine **404828-28-0P**, [2-(3-Ethynylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl) amine **404828-29-1P**, [2-(3-Methylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl) amine **404828-31-5P**, [2-(3,5-Difluorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl) amine **404828-32-6P**, [2-(3-Chloro-4-fluorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl) amine **404828-34-8P**, (5-Methyl-2H-pyrazol-3-yl) [2-(3-trifluoromethylphenyl)quinazolin-4-yl] amine **404828-35-9P**, [2-(3-Cyanophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl) amine **404828-36-0P**, [2-(3-Isopropylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl) amine **404828-37-1P**, (5-Methyl-2H-pyrazol-3-yl) (2-pyridin-3-ylquinazolin-4-yl) amine **404828-38-2P**, [2-(3-Acetylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl) amine **404828-39-3P**, [2-(3,5-Bis(trifluoromethyl)phenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl) amine **404828-40-6P**, [2-(3-Hydroxymethylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl) amine **404828-41-7P**, (5-Methyl-2H-pyrazol-3-yl) [2-(3-phenoxyphenyl)quinazolin-4-yl] amine **404828-42-8P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3-phenoxyphenyl)quinazolin-4-yl] amine **404828-43-9P** **404828-44-0P**, (2-Phenylquinazolin-4-yl) (2H-pyrazol-3-yl) amine **404828-45-1P**, (2H-Pyrazol-3-yl) (2-pyridin-4-ylquinazolin-4-yl) amine **404828-46-2P**, (5-Ethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl) amine **404828-47-3P**, (2-Phenylquinazolin-4-yl) (5-propyl-2H-pyrazol-3-yl) amine **404828-48-4P**, (5-Isopropyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl) amine **404828-49-5P**, (5-tert-Butyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl) amine **404828-50-8P**, (5-tert-Butyl-2H-pyrazol-3-yl) (2-pyridin-4-ylquinazolin-4-yl) amine **404828-51-9P**, (5-Cyclopentyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl) amine **404828-52-0P**, (5-Phenyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl) amine **404828-53-1P**, (5-Carboxy-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl) amine **404828-55-3P**, (5-Hydroxymethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl) amine **404828-56-4P**,


(5-Methoxymethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl) amine
404828-57-5P, [5-(3-Hydroxypropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl) amine **404828-59-7P**, [5-(3-Methoxypropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl) amine **404828-60-0P**, [5-(3-Aminopropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl) amine **404828-62-2P**, (5-Isopropylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl) amine **404828-63-3P**, (5-Allylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl) amine **404828-64-4P**, [5-(2-Methoxyethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl) amine **404828-65-5P**, (5-Benzylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl) amine **404828-66-6P**, (5-Cyclohexylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl) amine **404828-67-7P**, (5-Diethylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl) amine **404828-68-8P**, [5-(Benzylmethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl) amine **404828-69-9P**, (2-Phenylquinazolin-4-yl) (5-propylcarbamoyl-2H-pyrazol-3-yl) amine **404828-70-2P**, [5-(Ethylisopropylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl) amine **404828-71-3P**, (5-Cyclopropylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl) amine **404828-72-4P**, (5-Isobutylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl) amine **404828-73-5P**, [5-((3S)-3-Methoxymethylpyrrolidine-1-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl) amine **404828-74-6P**, (2-Phenylquinazolin-4-yl) (5-m-tolylcarbamoyl-2H-pyrazol-3-yl) amine **404828-75-7P**, (2-Phenylquinazolin-4-yl) (5-p-tolylcarbamoyl-2H-pyrazol-3-yl) amine **404828-76-8P**, (5-Methylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl) amine **404828-77-9P**, [5-(Morpholine-4-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl) amine **404828-78-0P**, [5-(1-Methylpiperazine-4-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl) amine **404828-79-1P**, [5-(2-Hydroxyethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl) amine **404828-80-4P**, (5-Carbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl) amine **404828-82-6P**, (4-Bromo-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl) amine **404828-83-7P**, (4-Bromo-5-methyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl) amine **404828-84-8P**, (4-Cyano-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl) amine **404828-85-9P**, (5-Methyl-2H-pyrazol-3-yl) (2-morpholin-4-ylquinazolin-4-yl) amine **404828-86-0P**, (5-Methyl-2H-pyrazol-3-yl) (2-piperazin-1-ylquinazolin-4-yl) amine **404828-87-1P**, [2-(4-Methylpiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl) amine **404828-88-2P**, [2-(4-Methylpiperazin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl) amine **404828-89-3P**, (5-Methyl-2H-pyrazol-3-yl) (2-piperidin-1-ylquinazolin-4-yl) amine **404828-90-6P**, [2-(Azepan-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl) amine **404828-91-7P**, [2-[4-(2-Hydroxyethyl)piperidin-1-yl]quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl) amine **404828-92-8P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-methylpiperidin-1-yl)quinazolin-4-yl] amine **404828-94-0P**, [2-(1,4-Dioxo-8-azaspiro[4.5]dec-8-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl) amine **404828-95-1P**, [2-(4-Cyclopentylaminopiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl) amine **404828-96-2P**, [2-(4-Hydroxypiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl) amine **404828-97-3P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-hydroxy-4-phenylpiperidin-1-yl)quinazolin-4-yl] amine **404828-98-4P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(1,3-dihydroisoindol-2-yl)quinazolin-4-yl] amine **404828-99-5P**, [2-(Azepan-1-yl)quinazolin-4-yl] (5-cyclopropyl-2H-pyrazol-3-yl) amine **404829-00-1P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dihydro-1H-isoquinolin-2-yl)quinazolin-4-yl] amine **404829-01-2P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(2,3-dihydroindol-

1-yl)quinazolin-4-yl]amine **404829-02-3P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(4-hydroxymethylpiperidin-1-yl)quinazolin-4-yl]amine **404829-03-4P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dihydro-2H-quinolin-1-yl)quinazolin-4-yl]amine **404829-05-6P**, 5-(Piperidine-1-carbonyl)-2H-pyrazol-3-yl-[2-(piperidine-1-yl)quinazolin-4-yl]amine **404829-06-7P**, (5-Hydroxymethyl-2H-pyrazol-3-yl)[2-(piperidin-1-yl)quinazolin-4-yl]amine **404829-07-8P**, (5-Carbamoyl-2H-pyrazol-3-yl)[2-(piperidin-1-yl)quinazolin-4-yl]amine **404829-08-9P**, (5-Carbamoyl-2H-pyrazol-3-yl)[2-(4-methylpiperidin-1-yl)quinazolin-4-yl]amine **404829-54-5P**, (5-Methyl-2H-pyrazol-3-yl)-(2-pyridin-4-ylthieno[3,2-d]pyrimidin-4-yl)amine **404829-55-6P**, (5-Methyl-2H-pyrazol-3-yl)-(2-phenylpyrido[3,4-d]pyrimidin-4-yl)amine **404829-56-7P**, (5-Methyl-2H-pyrazol-3-yl)-(2-phenylpyrido[2,3-d]pyrimidin-4-yl)amine **404829-57-8P**, (5-Cyclopropyl-2H-pyrazol-3-yl)-(2-phenylpyrido[3,4-d]pyrimidin-4-yl)amine **404829-60-3P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(4-methylpiperidin-1-yl)pyrrolo[3,2-d]pyrimidin-4-yl]amine **404845-75-6P**
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; preparation of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-60-4 CAPLUS


CN 4-Quinazolinamine, 2-(2-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
 (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-61-5 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-62-6 CAPLUS


CN 4-Quinazolinamine, 2-(2,5-dimethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-63-7 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-64-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-65-9 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-66-0 CAPLUS


CN Ethanone, 1-[2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-67-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,3-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-68-2 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-69-3 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-70-6 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-2-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-71-7 CAPLUS


CN Phenol, 2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-72-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-73-9 CAPLUS


CN 4-Quinazolinamine, N-[5-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-74-0 CAPLUS


CN 4-Quinazolinamine, N-[4-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-75-1 CAPLUS


CN 4-Quinazolinamine, N-(4-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-76-2 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-77-3 CAPLUS


CN 4-Quinazolinamine, N-(5-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-78-4 CAPLUS


CN 4-Quinazolinamine, N-(4,5-diphenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-79-5 CAPLUS


CN 1H-Pyrazole-4-carboxamide, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-80-8 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404826-81-9 CAPLUS

CN 3H-Pyrazol-3-one, 1,2-dihydro-5-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 404826-82-0 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-83-1 CAPLUS


CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-35-6 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-56-1 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-naphthalenyl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-08-6 CAPLUS


CN 4-Quinazolinamine, 5,6,7,8-tetrahydro-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-09-7 CAPLUS


CN 5H-Cycloheptapyrimidin-4-amine, 6,7,8,9-tetrahydro-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-10-0 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-11-1 CAPLUS


CN 4-Quinazolinamine, 7-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-12-2 CAPLUS


CN 4-Quinazolinamine, 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-13-3 CAPLUS


CN 4-Quinazolinamine, 2-cyclohexyl-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-14-4 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-15-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-16-6 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-17-7 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-18-8 CAPLUS


CN Benzonitrile, 4-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-19-9 CAPLUS


CN 4-Quinazolinamine, 2-(3-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-20-2 CAPLUS


CN 4-Quinazolinamine, 2-[4-(ethylthio)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-21-3 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-22-4 CAPLUS


CN 4-Quinazolinamine, 2-[4-(1,1-dimethylethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-23-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-24-6 CAPLUS


CN 4-Quinazolinamine, 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-25-7 CAPLUS


CN 4-Quinazolinamine, 2-[4-(dimethylamino)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-26-8 CAPLUS


CN 4-Quinazolinamine, 2-(3-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-27-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dichlorophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-28-0 CAPLUS


CN 4-Quinazolinamine, 2-(3-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-29-1 CAPLUS


CN 4-Quinazolinamine, 2-(3-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-31-5 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-32-6 CAPLUS


CN 4-Quinazolinamine, 2-(3-chloro-4-fluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-34-8 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-35-9 CAPLUS


CN Benzonitrile, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-36-0 CAPLUS


CN 4-Quinazolinamine, 2-[3-(1-methylethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-37-1 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-pyridinyl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-38-2 CAPLUS


CN Ethanone, 1-[3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-39-3 CAPLUS


CN 4-Quinazolinamine, 2-[3,5-bis(trifluoromethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-40-6 CAPLUS


CN Benzenemethanol, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-41-7 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-42-8 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-43-9 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-thienyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-44-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazol-3-yl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-45-1 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-46-2 CAPLUS


CN 4-Quinazolinamine, N-(5-ethyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-47-3 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-propyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-48-4 CAPLUS

CN 4-Quinazolinamine, N-[5-(1-methylethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-49-5 CAPLUS

CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-phenyl-


(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-50-8 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-51-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopentyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-52-0 CAPIUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404828-53-1 CAPIUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-55-3 CAPLUS

CN 1H-Pyrazole-3-methanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-56-4 CAPLUS


CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-57-5 CAPLUS

CN 1H-Pyrazole-3-propanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-59-7 CAPLUS

CN 4-Quinazolinamine, N-[5-(3-methoxypropyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404828-60-0 CAPLUS

CN 4-Quinazolinamine, N-[5-(3-aminopropyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404828-62-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-63-3 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 404828-64-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-methoxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-65-5 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(phenylmethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-66-6 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-cyclohexyl-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-67-7 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N,N-diethyl-5-[(2-phenyl-4-quinazolinyl)amino]-
(9CI) (CA INDEX NAME)

RN 404828-68-8 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-phenylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-69-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-propyl-
(9CI) (CA INDEX NAME)


RN 404828-70-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-ethyl-N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-71-3 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-cyclopropyl-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-72-4 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(2-methylpropyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-73-5 CAPLUS


CN Pyrrolidine, 3-(methoxymethyl)-1-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 404828-74-6 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(3-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-75-7 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(4-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-76-8 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-methyl-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-77-9 CAPLUS

CN Morpholine, 4-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404828-78-0 CAPLUS

CN Piperazine, 1-methyl-4-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404828-79-1 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-hydroxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-80-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-82-6 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404828-83-7 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI)
(CA INDEX NAME)

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-84-8 CAPLUS


CN 1H-Pyrazole-4-carbonitrile, 3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-85-9 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-86-0 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-87-1 CAPLUS


CN 4-Quinazolinamine, 2-(4-methyl-1-piperidinyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-88-2 CAPLUS


CN 4-Quinazolinamine, 2-(4-methyl-1-piperazinyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-89-3 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-piperidinyl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-90-6 CAPLUS


CN 4-Quinazolinamine, 2-(hexahydro-1H-azepin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-91-7 CAPLUS


CN 4-Piperidineethanol, 1-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-92-8 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(4-methyl-1-piperidinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-94-0 CAPLUS


CN 4-Quinazolinamine, 2-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-95-1 CAPLUS


CN 4-Quinazolinamine, 2-[4-(cyclopentylamino)-1-piperidinyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-96-2 CAPLUS


CN 4-Piperidinol, 1-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-97-3 CAPLUS


CN 4-Piperidinol, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-4-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-98-4 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1,3-dihydro-2H-isoindol-2-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-99-5 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(hexahydro-1H-azepin-1-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-00-1 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2'-(3,4-dihydro-2(1H)-isoquinolinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-01-2 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(2,3-dihydro-1H-indol-1-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-02-3 CAPLUS


CN 4-Piperidinemethanol, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-03-4 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-1(2H)-quinolinyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-05-6 CAPLUS

CN Piperidine, 1-[[5-[[2-(1-piperidinyl)-4-quinazolinyl]amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404829-06-7 CAPLUS

CN 1H-Pyrazole-3-methanol, 5-[[2-(1-piperidinyl)-4-quinazolinyl]amino]- (9CI)
(CA INDEX NAME)


RN 404829-07-8 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[[2-(1-piperidinyl)-4-quinazolinyl]amino]-
(9CI) (CA INDEX NAME)




RN 404829-08-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[[2-(4-methyl-1-piperidiny)]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 404829-54-5 CAPLUS


CN Thieno[3,2-d]pyrimidin-4-amine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-55-6 CAPLUS ;


CN Pyrido[3,4-d]pyrimidin-4-amine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-56-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl-
(9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-57-8 CAPLUS

09/624,800

Thomas McKenzie


CN Pyrido[3,4-d]pyrimidin-4-amine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-phenyl-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-60-3 CAPLUS


CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(4-methyl-1-piperidinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404845-75-6 CAPLUS

CN 1H-Purin-6-amine, 2-(4-methyl-1-piperidinyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


IT **404828-81-5**, 5-(2-Phenylquinazolin-4-ylamino)-1H-pyrazole-3-carboxylic acid 2,5-dioxypyrrolidin-1-yl ester

RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; preparation of heterocyclpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404828-81-5 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]oxy]- (9CI) (CA INDEX NAME)



L11 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN

2002:220583 Document No. 136:247583 Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease. Davies, Robert; Bebbington, David; Knegetel, Ronald; Wannamaker, Marion; Li, Pan; Forester, Cornelia; Pierce, Albert; Kay, David (Vertex Pharmaceuticals Incorporated, USA). PCT Int. Appl. WO 2002022607 A1 20020321, 373 pp. DESIGNATED STATES: W: AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR.

(English). CODEN: PIXXD2.. APPLICATION: WO 2001-US28940 20010914.
PRIORITY: US 2000-PV232795 20000915; US 2000-PV257887 20001221; US 2001-PV286949 20010427.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002022607	A1	20020321	WO 2001-US28940	20010914
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2001091013	A5	20020326	AU 2001-91013	20010914
US 2003055044	A1	20030320	US 2001-953505	20010914
US 6638926	B2	20031028		
US 2003064981	A1	20030403	US 2001-952836	20010914
US 6613776	B2	20030902		
US 2003064982	A1	20030403	US 2001-952875	20010914
US 2003073687	A1	20030417	US 2001-952671	20010914
US 6660731	B2	20031209		
US 2003078166	A1	20030424	US 2001-955601	20010914
US 6696452	B2	20040224		
US 2003083327	A1	20030501	US 2001-952833	20010914
US 6610677	B2	20030826		
BR 2001014088	A	20030617	BR 2001-14088	20010914
EP 1318997	A1	20030618	EP 2001-971082	20010914
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004509117	T2	20040325	JP 2002-526860	20010914
US 2004097501	A1	20040520	US 2001-953471	20010914
EP 1345922	A1	20030924	EP 2001-271061	20011219
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
EP 1355905	A1	20031029	EP 2001-273861	20011219
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
NZ 526472	A	20040430	NZ 2001-526472	20011219
JP 2004518743	T2	20040624	JP 2002-565976	20011219
JP 2004519479	T2	20040702	JP 2002-567928	20011219
NO 2003001191	A	20030513	NO 2003-1191	20030314
NO 2003002704	A	20030821	NO 2003-2704	20030613
US 2004116454	A1	20040617	US 2003-692355	20031023
US 2004157893	A1	20040812	US 2003-722374	20031125
US 2004132781	A1	20040708	US 2003-736426	20031215
US 2004167141	A1	20040826	US 2004-775699	20040210
IT 404826-20-6P,				
[2-(3,4-Dichlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine				
404826-21-7P,				
[2-(4-Bromophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine				
404826-22-8P,				


(2-Biphenyl-4-ylquinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine
404826-23-9P, [2-(4-Ethynylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-54-2P**, (5-Methoxycarbonyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-58-6P**,
 (5-Benzyloxypropyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
404828-61-1P, [5-(3-tert-Butoxycarbonylaminoethyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404829-04-5P**,
 (5-Methoxycarbonyl-2H-pyrazol-3-yl) [2-(piperidine-1-yl)quinazolin-4-yl]amine

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(protein kinase inhibitor; preparation of heterocyclpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-20-6 CAPLUS


CN 4-Quinazolinamine, 2-(3,4-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-21-7 CAPLUS


CN 4-Quinazolinamine, 2-(4-bromophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-22-8 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-4-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-23-9 CAPLUS


CN 4-Quinazolinamine, 2-(4-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404828-54-2 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]-, methyl
ester (9CI) (CA INDEX NAME)



RN 404828-58-6 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-[5-[3-(phenylmethoxy)propyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




Ph-CH₂-O-(CH₂)₃

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404828-61-1 CAPLUS

CN Carbamic acid, [3-[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 404829-04-5 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[[2-(1-piperidiny)-4-quinazolinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



IT 404826-60-4P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-methylphenyl)quinazolin-4-yl]amine 404826-61-5P, [2-(2,4-Difluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-62-6P, [2-(2,5-Dimethoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-63-7P, [2-(2-Chlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-64-8P, [2-(2-Methoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-65-9P, [2-(2,6-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-66-0P, [2-(2-Acetylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-67-1P, [2-(2,3-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-68-2P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-69-3P, [2-(2-Ethylphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-70-6P, (2-Biphenyl-2-yl)quinazolin-4-yl(5-methyl-2H-pyrazol-3-yl)amine 404826-71-7P, [2-(2-Hydroxyphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-72-8P, [2-(2-

Ethoxyphenyl)quinazolin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine
404826-73-9P, [5-(Thiophen-2-yl)-2H-pyrazol-3-yl] [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-74-0P**,
[4-(Thiophen-2-yl)-2H-pyrazol-3-yl] [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-75-1P**, (4-Phenyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-76-2P**,
(5-tert-Butyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-77-3P**, (5-Phenyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-78-4P**,
(4,5-Diphenyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-79-5P**, (4-Carbamoyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-80-8P**,
(2H-Pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-81-9P**, (5-Hydroxy-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-82-0P**,
(5-Cyclopropyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-83-1P**, (5-Methoxymethyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-35-6P**,
[2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404827-56-1P**, (5-Methyl-2H-pyrazol-3-yl) [2-(2-naphthyl-1-yl)quinazolin-4-yl]amine **404828-08-6P**, (5-Methyl-2H-pyrazol-3-yl) (2-phenyl-5,6,7,8-tetrahydroquinazolin-4-yl)amine **404828-09-7P**,
(5-Methyl-2H-pyrazol-3-yl) (2-phenyl-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl)amine **404828-10-0P**,
(5-Methyl-2H-pyrazol-3-yl) (2-pyridin-4-ylquinazolin-4-yl)-amine **404828-11-1P**, (7-Chloro-2-pyridin-4-ylquinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine **404828-12-2P**, (6-Chloro-2-pyridin-4-ylquinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine **404828-13-3P**,
(2-Cyclohexylquinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine **404828-14-4P**, (5-Methyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-15-5P**, [2-(4-Iodophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-16-6P**, [2-(4-Chlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-17-7P**, [2-(3,5-Dichlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-18-8P**, [2-(4-Cyanophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-19-9P**,
[2-(3-Iodophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-20-2P**, [2-(4-Ethylsulfanylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-21-3P**, (5-Cyclopropyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-22-4P**,
[2-(4-tert-Butylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-23-5P**, [2-(4-Chlorophenyl)quinazolin-4-yl] (5-cyclopropyl-2H-pyrazol-3-yl)amine **404828-24-6P**, (2-Benzo[1,3]dioxol-5-ylquinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine **404828-25-7P**,
[2-(4-Dimethylaminophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-26-8P**, [2-(3-Methoxyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-27-9P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dichlorophenyl)quinazolin-4-yl]amine **404828-28-0P**,
[2-(3-Ethynylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-29-1P**, [2-(3-Methylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-31-5P**, [2-(3,5-Difluorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-32-6P**, [2-(3-Chloro-4-fluorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-34-8P**, (5-Methyl-2H-pyrazol-3-yl) [2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine **404828-35-9P**, [2-(3-Cyanophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-36-0P**, [2-(3-Isopropylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine


404828-37-1P, (5-Methyl-2H-pyrazol-3-yl)(2-pyridin-3-ylquinazolin-4-yl)amine **404828-38-2P**, [2-(3-Acetylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-39-3P**, [2-(3,5-Bis(trifluoromethyl)phenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-40-6P**, [2-(3-Hydroxymethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-41-7P**, (5-Methyl-2H-pyrazol-3-yl)[2-(3-phenoxyphenyl)quinazolin-4-yl]amine **404828-42-8P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3-phenoxyphenyl)quinazolin-4-yl]amine **404828-43-9P** **404828-44-0P**, (2-Phenylquinazolin-4-yl)(2H-pyrazol-3-yl)amine **404828-45-1P**, (2H-Pyrazol-3-yl)(2-pyridin-4-ylquinazolin-4-yl)amine **404828-46-2P**, (5-Ethyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-47-3P**, (2-Phenylquinazolin-4-yl)(5-propyl-2H-pyrazol-3-yl)amine **404828-48-4P**, (5-Isopropyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-49-5P**, (5-tert-Butyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-50-8P**, (5-tert-Butyl-2H-pyrazol-3-yl)(2-pyridin-4-ylquinazolin-4-yl)amine **404828-51-9P**, (5-Cyclopentyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-52-0P**, (5-Phenyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-53-1P**, (5-Carboxy-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-55-3P**, (5-Hydroxymethyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-56-4P**, (5-Methoxymethyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-57-5P**, [5-(3-Hydroxypropyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine **404828-59-7P**, [5-(3-Methoxypropyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine **404828-60-0P**, [5-(3-Aminopropyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine **404828-62-2P**, (5-Isopropylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-63-3P**, (5-Allylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-64-4P**, [5-(2-Methoxyethylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine **404828-65-5P**, (5-Benzylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-66-6P**, (5-Cyclohexylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-67-7P**, (5-Diethylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-68-8P**, [5-(Benzylmethylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine **404828-69-9P**, (2-Phenylquinazolin-4-yl)(5-propylcarbamoyl-2H-pyrazol-3-yl)amine **404828-70-2P**, [5-(Ethylisopropylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine **404828-71-3P**, (5-Cyclopropylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-72-4P**, (5-Isobutylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-73-5P**, [5-((3S)-3-Methoxymethylpyrrolidine-1-carbonyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine **404828-74-6P**, (2-Phenylquinazolin-4-yl)(5-m-tolylcarbamoyl-2H-pyrazol-3-yl)amine **404828-75-7P**, (2-Phenylquinazolin-4-yl)(5-p-tolylcarbamoyl-2H-pyrazol-3-yl)amine **404828-76-8P**, (5-Methylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-77-9P**, [5-(Morpholine-4-carbonyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine **404828-78-0P**, [5-(1-Methylpiperazine-4-carbonyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine **404828-79-1P**, [5-(2-Hydroxyethylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine **404828-80-4P**, (5-Carbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-82-6P**, (4-Bromo-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-83-7P**, (4-Bromo-5-methyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-84-8P**, (4-Cyano-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-85-9P**, (5-Methyl-2H-pyrazol-3-yl)(2-morpholin-4-

ylquinazolin-4-yl)amine **404828-86-0P**, (5-Methyl-2H-pyrazol-3-yl)(2-piperazin-1-ylquinazolin-4-yl)amine **404828-87-1P**, [2-(4-Methylpiperidin-1-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-88-2P**, [2-(4-Methylpiperazin-1-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-89-3P**, (5-Methyl-2H-pyrazol-3-yl)(2-piperidin-1-ylquinazolin-4-yl)amine **404828-90-6P**, [2-(Azepan-1-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-91-7P**, [2-[4-(2-Hydroxyethyl)piperidin-1-yl]quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-92-8P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(4-methylpiperidin-1-yl)quinazolin-4-yl]amine **404828-94-0P**, [2-(1,4-Dioxo-8-azaspiro[4.5]dec-8-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-95-1P**, [2-(4-Cyclopentylaminopiperidin-1-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-96-2P**, [2-(4-Hydroxypiperidin-1-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-97-3P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(4-hydroxy-4-phenylpiperidin-1-yl)quinazolin-4-yl]amine **404828-98-4P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(1,3-dihydroisoindol-2-yl)quinazolin-4-yl]amine **404828-99-5P**, [2-(Azepan-1-yl)quinazolin-4-yl](5-cyclopropyl-2H-pyrazol-3-yl)amine **404829-00-1P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dihydro-1H-isoquinolin-2-yl)quinazolin-4-yl]amine **404829-01-2P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(2,3-dihydroindol-1-yl)quinazolin-4-yl]amine **404829-02-3P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(4-hydroxymethylpiperidin-1-yl)quinazolin-4-yl]amine **404829-03-4P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dihydro-2H-quinolin-1-yl)quinazolin-4-yl]amine **404829-05-6P**, 5-(Piperidine-1-carbonyl)-2H-pyrazol-3-yl-[2-(piperidine-1-yl)quinazolin-4-yl]amine **404829-06-7P**, (5-Hydroxymethyl-2H-pyrazol-3-yl)[2-(piperidin-1-yl)quinazolin-4-yl]amine **404829-07-8P**, (5-Carbamoyl-2H-pyrazol-3-yl)[2-(piperidin-1-yl)quinazolin-4-yl]amine **404829-08-9P**, (5-Carbamoyl-2H-pyrazol-3-yl)[2-(4-methylpiperidin-1-yl)quinazolin-4-yl]amine **404829-54-5P**, (5-Methyl-2H-pyrazol-3-yl)-(2-pyridin-4-ylthieno[3,2-d]pyrimidin-4-yl)amine **404829-55-6P**, (5-Methyl-2H-pyrazol-3-yl)-(2-phenylpyrido[3,4-d]pyrimidin-4-yl)amine **404829-56-7P**, (5-Methyl-2H-pyrazol-3-yl)-(2-phenylpyrido[2,3-d]pyrimidin-4-yl)amine **404829-57-8P**, (5-Cyclopropyl-2H-pyrazol-3-yl)-(2-phenylpyrido[3,4-d]pyrimidin-4-yl)amine **404829-60-3P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(4-methylpiperidin-1-yl)pyrrolo[3,2-d]pyrimidin-4-yl]amine **404845-75-6P 404872-73-7P 404872-76-0P 404872-96-4P 404873-05-8P 404873-45-6P 404873-47-8P 404873-48-9P**
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; preparation of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-60-4 CAPLUS


CN 4-Quinazolinamine, 2-(2-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-(9CI)
 (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-61-5 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-62-6 CAPLUS


CN 4-Quinazolinamine, 2-(2,5-dimethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-63-7 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-64-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-65-9 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-66-0 CAPLUS


CN Ethanone, 1-[2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-67-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,3-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-68-2 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-69-3 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-70-6 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-2-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-71-7 CAPLUS


CN Phenol, 2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-72-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-73-9 CAPLUS


CN 4-Quinazolinamine, N-[5-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-74-0 CAPLUS


CN 4-Quinazolinamine, N-[4-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-75-1 CAPLUS


CN 4-Quinazolinamine, N-(4-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-76-2 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-77-3 CAPLUS


CN 4-Quinazolinamine, N-(5-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-78-4 CAPLUS


CN 4-Quinazolinamine, N-(4,5-diphenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-79-5 CAPLUS


CN 1H-Pyrazole-4-carboxamide, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-80-8 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404826-81-9 CAPLUS

CN 3H-Pyrazol-3-one, 1,2-dihydro-5-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 404826-82-0 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-83-1 CAPLUS


CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-35-6 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-56-1 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-naphthalenyl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-08-6 CAPLUS


CN 4-Quinazolinamine, 5,6,7,8-tetrahydro-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-09-7 CAPLUS


CN 5H-Cycloheptapyrimidin-4-amine, 6,7,8,9-tetrahydro-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-10-0 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-11-1 CAPLUS


CN 4-Quinazolinamine, 7-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-12-2 CAPLUS


CN 4-Quinazolinamine, 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-13-3 CAPLUS


CN 4-Quinazolinamine, 2-cyclohexyl-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-14-4 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-15-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE.

RN 404828-16-6 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-17-7 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-18-8 CAPLUS


CN Benzonitrile, 4-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-19-9 CAPLUS


CN 4-Quinazolinamine, 2-(3-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-20-2 CAPLUS


CN 4-Quinazolinamine, 2-[4-(ethylthio)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-21-3 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-22-4 CAPLUS


CN 4-Quinazolinamine, 2-[4-(1,1-dimethylethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-23-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-24-6 CAPLUS


CN 4-Quinazolinamine, 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-25-7 CAPLUS


CN 4-Quinazolinamine, 2-[4-(dimethylamino)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-26-8 CAPLUS


CN 4-Quinazolinamine, 2-(3-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-27-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dichlorophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-28-0 CAPLUS


CN 4-Quinazolinamine, 2-(3-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-29-1 CAPLUS


CN 4-Quinazolinamine, 2-(3-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-31-5 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-32-6 CAPLUS


CN 4-Quinazolinamine, 2-(3-chloro-4-fluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-34-8 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-35-9 CAPLUS


CN Benzonitrile, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404828-36-0 CAPLUS

CN 4-Quinazolinamine, 2-[3-(1-methylethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-37-1 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-pyridinyl)- (9CI)
(CA INDEX NAME)

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404828-38-2 CAPLUS

CN Ethanone, 1-[3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(9CI) (CA INDEX NAME)

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-39-3 CAPLUS


CN 4-Quinazolinamine, 2-[3,5-bis(trifluoromethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-40-6 CAPLUS


CN Benzenemethanol, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-41-7 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-42-8 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-43-9 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-thienyl)- (9CI) (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-44-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazol-3-yl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-45-1 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-46-2 CAPLUS


CN 4-Quinazolinamine, N-(5-ethyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-47-3 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-propyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-48-4 CAPLUS

CN 4-Quinazolinamine, N-[5-(1-methylethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-49-5 CAPLUS

CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-phenyl-


(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-50-8 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-51-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopentyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-52-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-53-1 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI)
(CA INDEX NAME)




09/624,800

Thomas McKenzie


RN 404828-55-3 CAPLUS

CN 1H-Pyrazole-3-methanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-56-4 CAPLUS


CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-57-5 CAPLUS

CN 1H-Pyrazole-3-propanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-59-7 CAPLUS

CN 4-Quinazolinamine, N-[5-(3-methoxypropyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404828-60-0 CAPLUS

CN 4-Quinazolinamine, N-[5-(3-aminopropyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404828-62-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-63-3 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 404828-64-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-methoxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-65-5 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(phenylmethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-66-6 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-cyclohexyl-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-67-7 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N,N-diethyl-5-[(2-phenyl-4-quinazolinyl)amino]-
(9CI) (CA INDEX NAME)




RN 404828-68-8 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-phenylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-69-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-propyl-
(9CI) (CA INDEX NAME)


RN 404828-70-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-ethyl-N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-71-3 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-cyclopropyl-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-72-4 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(2-methylpropyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-73-5 CAPLUS


CN Pyrrolidine, 3-(methoxymethyl)-1-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 404828-74-6 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(3-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-75-7 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(4-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-76-8 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-methyl-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-77-9 CAPLUS

CN Morpholine, 4-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404828-78-0 CAPLUS

CN Piperazine, 1-methyl-4-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404828-79-1 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-hydroxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-80-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-82-6 CAPLUS


CN 4-Quinazolinamine, N-(4-bromo-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-83-7 CAPLUS


CN 4-Quinazolinamine, N-(4-bromo-5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-84-8 CAPLUS


CN 1H-Pyrazole-4-carbonitrile, 3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-85-9 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-86-0 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-87-1 CAPLUS


CN 4-Quinazolinamine, 2-(4-methyl-1-piperidinyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-88-2 CAPLUS


CN 4-Quinazolinamine, 2-(4-methyl-1-piperazinyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-89-3 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-piperidinyl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-90-6 CAPLUS


CN 4-Quinazolinamine, 2-(hexahydro-1H-azepin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-91-7 CAPLUS


CN 4-Piperidineethanol, 1-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-92-8 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(4-methyl-1-piperidinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-94-0 CAPLUS


CN 4-Quinazolinamine, 2-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-95-1 CAPLUS


CN 4-Quinazolinamine, 2-[4-(cyclopentylamino)-1-piperidinyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-96-2 CAPLUS


CN 4-Piperidinol, 1-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-97-3 CAPLUS


CN 4-Piperidinol, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-4-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-98-4 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1,3-dihydro-2H-isoindol-2-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-99-5 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(hexahydro-1H-azepin-1-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-00-1 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-2(1H)-isoquinolinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-01-2 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(2,3-dihydro-1H-indol-1-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-02-3 CAPLUS


CN 4-Piperidinemethanol, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-03-4 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-1(2H)-quinolinyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-05-6 CAPLUS

CN Piperidine, 1-[[5-[[2-(1-piperidinyl)-4-quinazolinyl]amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404829-06-7 CAPLUS

CN 1H-Pyrazole-3-methanol, 5-[[2-(1-piperidinyl)-4-quinazolinyl]amino]- (9CI)
(CA INDEX NAME)


RN 404829-07-8 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[[2-(1-piperidinyl)-4-quinazolinyl]amino]-
(9CI) (CA INDEX NAME)




RN 404829-08-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[[2-(4-methyl-1-piperidinyl)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 404829-54-5 CAPLUS


CN Thieno[3,2-d]pyrimidin-4-amine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-55-6 CAPLUS


CN Pyrido[3,4-d]pyrimidin-4-amine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-56-7 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-57-8 CAPLUS


CN Pyrido[3,4-d]pyrimidin-4-amine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-phenyl-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-60-3 CAPLUS


CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(4-methyl-1-piperidinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404845-75-6 CAPLUS


CN 1H-Purin-6-amine, 2-(4-methyl-1-piperidinyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404872-73-7 CAPLUS


CN Isoxazolo[4,5-d]pyrimidin-7-amine, N-(5-methyl-1H-pyrazol-3-yl)-5-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404872-76-0 CAPLUS


CN Isothiazolo[4,5-d]pyrimidin-7-amine, N-(5-methyl-1H-pyrazol-3-yl)-5-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404872-96-4 CAPLUS


CN 5H-Pyrimido[4,5-d]azepin-4-amine, 6,7,8,9-tetrahydro-N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-05-8 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-45-6 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-naphthalenyl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-47-8 CAPLUS


CN 4-Quinazolinamine, 2-(1-isoquinolinyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-48-9 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-isoquinolinyl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


IT **404828-81-5**, 5-(2-Phenylquinazolin-4-ylamino)-1H-pyrazole-3-carboxylic acid 2,5-dioxopyrrolidin-1-yl ester

RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; preparation of heterocyclpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404828-81-5 CAPLUS


CN 2,5-Pyrrolidinedione, 1-[[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]oxy]- (9CI) (CA INDEX NAME)



L11 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN
 2002:220582 Document No. 136:247582 Preparation of pyrazolamines and analogs
 as protein kinase inhibitors for treatment of cancer, diabetes, and
 Alzheimer's disease. Bebbington, David; Binch, Hayley; Knegtel, Ronald;
 Golec, Julian M. C.; Patel, Sanjay; Charrier, Jean-Damien; Kay, David;
 Davies, Robert; Li, Pan; Wannamaker, Marion; Forster, Cornelia; Pierce,
 Albert (Vertex Pharmaceuticals Incorporated, USA). PCT Int. Appl. WO
 2002022606 A1 20020321, 355 pp. DESIGNATED STATES: W: AE, AG, AL, AM,
 AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK,
 DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
 KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
 MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,
 TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ,
 TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA,
 GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR.
 (English). CODEN: PIXXD2. APPLICATION: WO 2001-US28803 20010914.
 PRIORITY: US 2000-PV232795 20000915; US 2000-PV257887 20001221; US
 2001-PV286949 20010427.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002022606	A1	20020321	WO 2001-US28803	20010914
W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
AU 2001090944	A5	20020326	AU 2001-90944	20010914
US 2003055044	A1	20030320	US 2001-953505	20010914
US 6638926	B2	20031028		
US 2003064981	A1	20030403	US 2001-952836	20010914
US 6613776	B2	20030902		


US 2003064982	A1	20030403	US 2001-952875	20010914
US 2003073687	A1	20030417	US 2001-952671	20010914
US 6660731	B2	20031209		
US 2003078166	A1	20030424	US 2001-955601	20010914
US 6696452	B2	20040224		
US 2003083327	A1	20030501	US 2001-952833	20010914
US 6610677	B2	20030826		
EP 1317448	A1	20030611	EP 2001-971006	20010914
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004509116	T2	20040325	JP 2002-526859	20010914
US 2004097501	A1	20040520	US 2001-953471	20010914
EP 1345922	A1	20030924	EP 2001-271061	20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1355905	A1	20031029	EP 2001-273861	20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 526472	A	20040430	NZ 2001-526472	20011219
JP 2004518743	T2	20040624	JP 2002-565976	20011219
JP 2004519479	T2	20040702	JP 2002-567928	20011219
NO 2003001189	A	20030513	NO 2003-1189	20030314
NO 2003002704	A	20030821	NO 2003-2704	20030613
US 2004116454	A1	20040617	US 2003-692355	20031023
US 2004157893	A1	20040812	US 2003-722374	20031125
US 2004132781	A1	20040708	US 2003-736426	20031215
US 2004167141	A1	20040826	US 2004-775699	20040210
IT	404826-20-6P , [2-(3,4-Dichlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-21-7P , [2-(4-Bromophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-22-8P , (2-Biphenyl-4-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine 404826-23-9P , [2-(4-Ethynylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-54-2P , (5-Methoxycarbonyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-58-6P , (5-Benzyloxypropyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-61-1P , [5-(3-tert-Butoxycarbonylamino)propyl]-2H-pyrazol-3-yl(2-phenylquinazolin-4-yl)amine 404829-04-5P , (5-Methoxycarbonyl-2H-pyrazol-3-yl)[2-(piperidine-1-yl)quinazolin-4-yl]amine RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (protein kinase inhibitor; preparation of heterocyclic pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)			
RN	404826-20-6 CAPLUS			
CN	4-Quinazolinamine, 2-(3,4-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-(9CI) (CA INDEX NAME)			



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-21-7 CAPLUS


CN 4-Quinazolinamine, 2-(4-bromophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-22-8 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-4-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-23-9 CAPLUS


CN 4-Quinazolinamine, 2-(4-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404828-54-2 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]-, methyl
ester (9CI) (CA INDEX NAME)



RN 404828-58-6 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-[5-[3-(phenylmethoxy)propyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




Ph-CH₂-O-(CH₂)₃

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404828-61-1 CAPLUS

CN Carbamic acid, [3-[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 404829-04-5 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[[2-(1-piperidiny1)-4-quinazolinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



IT 404826-60-4P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-methylphenyl)quinazolin-4-yl]amine 404826-61-5P, [2-(2,4-Difluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-62-6P, [2-(2,5-Dimethoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-63-7P, [2-(2-Chlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-64-8P, [2-(2-Methoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-65-9P, [2-(2,6-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-66-0P, [2-(2-Acetylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-67-1P, [2-(2,3-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-68-2P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-69-3P, [2-(2-Ethylphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-70-6P, (2-Biphenyl-2-yl)quinazolin-4-yl(5-methyl-2H-pyrazol-3-yl)amine 404826-71-7P, [2-(2-Hydroxyphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-72-8P, [2-(2-

Ethoxyphenyl)quinazolin-4-yl] (5-Methyl-2H-pyrazol-3-yl) amine
404826-73-9P, [5-(Thiophen-2-yl)-2H-pyrazol-3-yl] [2-(2-trifluoromethylphenyl)quinazolin-4-yl] amine **404826-74-0P**,
[4-(Thiophen-2-yl)-2H-pyrazol-3-yl] [2-(2-trifluoromethylphenyl)quinazolin-4-yl] amine **404826-75-1P**, (4-Phenyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl] amine **404826-76-2P**,
(5-tert-Butyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl] amine **404826-77-3P**, (5-Phenyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl] amine **404826-78-4P**,
(4,5-Diphenyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl] amine **404826-79-5P**, (4-Carbamoyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl] amine **404826-80-8P**,
(2H-Pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl] amine **404826-81-9P**, (5-Hydroxy-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl] amine **404826-82-0P**,
(5-Cyclopropyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl] amine **404826-83-1P**, (5-Methoxymethyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl] amine **404827-35-6P**,
[2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl) amine **404827-56-1P**, (5-Methyl-2H-pyrazol-3-yl) [2-(2-naphthyl-1-yl)quinazolin-4-yl] amine **404828-08-6P**, (5-Methyl-2H-pyrazol-3-yl) (2-phenyl-5,6,7,8-tetrahydroquinazolin-4-yl) amine **404828-09-7P**,
(5-Methyl-2H-pyrazol-3-yl) (2-phenyl-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl) amine **404828-10-0P**,
(5-Methyl-2H-pyrazol-3-yl) (2-pyridin-4-ylquinazolin-4-yl) amine **404828-11-1P**, (7-Chloro-2-pyridin-4-ylquinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl) amine **404828-12-2P**, (6-Chloro-2-pyridin-4-ylquinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl) amine **404828-13-3P**,
(2-Cyclohexylquinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl) amine **404828-14-4P**, (5-Methyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl) amine **404828-15-5P**, [2-(4-Iodophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl) amine **404828-16-6P**, [2-(4-Chlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl) amine **404828-17-7P**, [2-(3,5-Dichlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl) amine **404828-18-8P**, [2-(4-Cyanophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl) amine **404828-19-9P**,
[2-(3-Iodophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl) amine **404828-20-2P**, [2-(4-Ethylsulfanylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl) amine **404828-21-3P**, (5-Cyclopropyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl) amine **404828-22-4P**,
[2-(4-tert-Butylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl) amine **404828-23-5P**, [2-(4-Chlorophenyl)quinazolin-4-yl] (5-cyclopropyl-2H-pyrazol-3-yl) amine **404828-24-6P**, (2-Benzo[1,3]dioxol-5-ylquinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl) amine **404828-25-7P**,
[2-(4-Dimethylaminophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl) amine **404828-26-8P**, [2-(3-Methoxyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl) amine **404828-27-9P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dichlorophenyl)quinazolin-4-yl] amine **404828-28-0P**,
[2-(3-Ethynylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl) amine **404828-29-1P**, [2-(3-Methylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl) amine **404828-31-5P**, [2-(3,5-Difluorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl) amine **404828-32-6P**, [2-(3-Chloro-4-fluorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl) amine **404828-34-8P**, (5-Methyl-2H-pyrazol-3-yl) [2-(3-trifluoromethylphenyl)quinazolin-4-yl] amine **404828-35-9P**, [2-(3-Cyanophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl) amine **404828-36-0P**, [2-(3-Isopropylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl) amine


404828-37-1P, (5-Methyl-2H-pyrazol-3-yl)(2-pyridin-3-ylquinazolin-4-yl)amine 404828-38-2P, [2-(3-Acetylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-39-3P, [2-(3,5-Bis(trifluoromethyl)phenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-40-6P, [2-(3-Hydroxymethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-41-7P, (5-Methyl-2H-pyrazol-3-yl)[2-(3-phenoxyphenyl)quinazolin-4-yl]amine 404828-42-8P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3-phenoxyphenyl)quinazolin-4-yl]amine 404828-43-9P 404828-44-0P, (2-Phenylquinazolin-4-yl)(2H-pyrazol-3-yl)amine 404828-45-1P, (2H-Pyrazol-3-yl)(2-pyridin-4-ylquinazolin-4-yl)amine 404828-46-2P, (5-Ethyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-47-3P, (2-Phenylquinazolin-4-yl)(5-propyl-2H-pyrazol-3-yl)amine 404828-48-4P, (5-Isopropyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-49-5P, (5-tert-Butyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-50-8P, (5-tert-Butyl-2H-pyrazol-3-yl)(2-pyridin-4-ylquinazolin-4-yl)amine 404828-51-9P, (5-Cyclopentyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-52-0P, (5-Phenyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-53-1P, (5-Carboxy-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-55-3P, (5-Hydroxymethyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-56-4P, (5-Methoxymethyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-57-5P, [5-(3-Hydroxypropyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-59-7P, [5-(3-Methoxypropyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-60-0P, [5-(3-Aminopropyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-62-2P, (5-Isopropylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-63-3P, (5-Allylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-64-4P, [5-(2-Methoxyethylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-65-5P, (5-Benzylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-66-6P, (5-Cyclohexylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-67-7P, (5-Diethylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-68-8P, [5-(Benzylmethylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-69-9P, (2-Phenylquinazolin-4-yl)(5-propylcarbamoyl-2H-pyrazol-3-yl)amine 404828-70-2P, [5-(Ethylisopropylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-71-3P, (5-Cyclopropylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-72-4P, (5-Isobutylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-73-5P, [5-((3S)-3-Methoxymethylpyrrolidine-1-carbonyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-74-6P, (2-Phenylquinazolin-4-yl)(5-m-tolylcarbamoyl-2H-pyrazol-3-yl)amine 404828-75-7P, (2-Phenylquinazolin-4-yl)(5-p-tolylcarbamoyl-2H-pyrazol-3-yl)amine 404828-76-8P, (5-Methylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-77-9P, [5-(Morpholine-4-carbonyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-78-0P, [5-(1-Methylpiperazine-4-carbonyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-79-1P, [5-(2-Hydroxyethylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-80-4P, (5-Carbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-82-6P, (4-Bromo-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-83-7P, (4-Bromo-5-methyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-84-8P, (4-Cyano-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-85-9P, (5-Methyl-2H-pyrazol-3-yl)(2-morpholin-4-

ylquinazolin-4-yl)amine **404828-86-0P**, (5-Methyl-2H-pyrazol-3-yl)(2-piperazin-1-ylquinazolin-4-yl)amine **404828-87-1P**, [2-(4-Methylpiperidin-1-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-88-2P**, [2-(4-Methylpiperazin-1-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-89-3P**, (5-Methyl-2H-pyrazol-3-yl)(2-piperidin-1-ylquinazolin-4-yl)amine **404828-90-6P**, [2-(Azepan-1-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-91-7P**, [2-[4-(2-Hydroxyethyl)piperidin-1-yl]quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-92-8P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(4-methylpiperidin-1-yl)quinazolin-4-yl]amine **404828-94-0P**, [2-(1,4-Dioxo-8-azaspiro[4.5]dec-8-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-95-1P**, [2-(4-Cyclopentylaminopiperidin-1-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-96-2P**, [2-(4-Hydroxypiperidin-1-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-97-3P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(4-hydroxy-4-phenylpiperidin-1-yl)quinazolin-4-yl]amine **404828-98-4P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(1,3-dihydroisoindol-2-yl)quinazolin-4-yl]amine **404828-99-5P**, [2-(Azepan-1-yl)quinazolin-4-yl](5-cyclopropyl-2H-pyrazol-3-yl)amine **404829-00-1P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dihydro-1H-isoquinolin-2-yl)quinazolin-4-yl]amine **404829-01-2P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(2,3-dihydroindol-1-yl)quinazolin-4-yl]amine **404829-02-3P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(4-hydroxymethylpiperidin-1-yl)quinazolin-4-yl]amine **404829-03-4P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dihydro-2H-quinolin-1-yl)quinazolin-4-yl]amine **404829-05-6P**, 5-(Piperidine-1-carbonyl)-2H-pyrazol-3-yl-[2-(piperidine-1-yl)quinazolin-4-yl]amine **404829-06-7P**, (5-Hydroxymethyl-2H-pyrazol-3-yl)[2-(piperidin-1-yl)quinazolin-4-yl]amine **404829-07-8P**, (5-Carbamoyl-2H-pyrazol-3-yl)[2-(piperidin-1-yl)quinazolin-4-yl]amine **404829-08-9P**, (5-Carbamoyl-2H-pyrazol-3-yl)[2-(4-methylpiperidin-1-yl)quinazolin-4-yl]amine **404829-54-5P**, (5-Methyl-2H-pyrazol-3-yl)-(2-pyridin-4-ylthieno[3,2-d]pyrimidin-4-yl)amine **404829-55-6P**, (5-Methyl-2H-pyrazol-3-yl)-(2-phenylpyrido[3,4-d]pyrimidin-4-yl)amine **404829-56-7P**, (5-Methyl-2H-pyrazol-3-yl)-(2-phenylpyrido[2,3-d]pyrimidin-4-yl)amine **404829-57-8P**, (5-Cyclopropyl-2H-pyrazol-3-yl)-(2-phenylpyrido[3,4-d]pyrimidin-4-yl)amine **404829-60-3P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(4-methylpiperidin-1-yl)pyrrolo[3,2-d]pyrimidin-4-yl]amine **404829-83-0P 404845-75-6P**
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; preparation of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-60-4 CAPLUS


CN 4-Quinazolinamine, 2-(2-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
 (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-61-5 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-62-6 CAPLUS


CN 4-Quinazolinamine, 2-(2,5-dimethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-63-7 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-64-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-65-9 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-66-0 CAPLUS


CN Ethanone, 1-[2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-67-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,3-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-68-2 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-69-3 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-70-6 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-2-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-71-7 CAPLUS


CN Phenol, 2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-72-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-73-9 CAPLUS


CN 4-Quinazolinamine, N-[5-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-74-0 CAPLUS


CN 4-Quinazolinamine, N-[4-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-75-1 CAPLUS


CN 4-Quinazolinamine, N-(4-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-76-2 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-77-3 CAPLUS


CN 4-Quinazolinamine, N-(5-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-78-4 CAPLUS


CN 4-Quinazolinamine, N-(4,5-diphenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-79-5 CAPLUS


CN 1H-Pyrazole-4-carboxamide, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-80-8 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404826-81-9 CAPLUS

CN 3H-Pyrazol-3-one, 1,2-dihydro-5-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 404826-82-0 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-83-1 CAPLUS


CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-35-6 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-56-1 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-naphthalenyl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-08-6 CAPLUS


CN 4-Quinazolinamine, 5,6,7,8-tetrahydro-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-09-7 CAPLUS


CN 5H-Cycloheptapyrimidin-4-amine, 6,7,8,9-tetrahydro-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-10-0 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-11-1 CAPLUS


CN 4-Quinazolinamine, 7-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-12-2 CAPLUS


CN 4-Quinazolinamine, 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-13-3 CAPLUS


CN 4-Quinazolinamine, 2-cyclohexyl-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-14-4 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404828-15-5 CAPLUS

CN 4-Quinazolinamine, 2-(4-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-16-6 CAPLUS

CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404828-17-7 CAPLUS

CN 4-Quinazolinamine, 2-(3,5-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-18-8 CAPLUS


CN Benzonitrile, 4-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-19-9 CAPLUS


CN 4-Quinazolinamine, 2-(3-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-20-2 CAPLUS


CN 4-Quinazolinamine, 2-[4-(ethylthio)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-21-3 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-22-4 CAPLUS


CN 4-Quinazolinamine, 2-[4-(1,1-dimethylethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-23-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-24-6 CAPLUS


CN 4-Quinazolinamine, 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-25-7 CAPLUS


CN 4-Quinazolinamine, 2-[4-(dimethylamino)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-26-8 CAPLUS


CN 4-Quinazolinamine, 2-(3-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-27-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dichlorophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-28-0 CAPLUS


CN 4-Quinazolinamine, 2-(3-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-29-1 CAPLUS


CN 4-Quinazolinamine, 2-(3-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-31-5 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-32-6 CAPLUS


CN 4-Quinazolinamine, 2-(3-chloro-4-fluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-34-8 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-35-9 CAPLUS


CN Benzonitrile, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404828-36-0 CAPLUS

CN 4-Quinazolinamine, 2-[3-(1-methylethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-37-1 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-pyridinyl)- (9CI)
(CA INDEX NAME)

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404828-38-2 CAPLUS

CN Ethanone, 1-[3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(9CI) (CA INDEX NAME)

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-39-3 CAPLUS


CN 4-Quinazolinamine, 2-[3,5-bis(trifluoromethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-40-6 CAPLUS


CN Benzenemethanol, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-41-7 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-42-8 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-43-9 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-thienyl)- (9CI) (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-44-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazol-3-yl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-45-1 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-46-2 CAPLUS


CN 4-Quinazolinamine, N-(5-ethyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-47-3 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-propyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-48-4 CAPLUS

CN 4-Quinazolinamine, N-[5-(1-methylethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-49-5 CAPLUS

CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-phenyl-


(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-50-8 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-51-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopentyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-52-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-53-1 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




09/624,800

Thomas McKenzie


RN 404828-55-3 CAPLUS

CN 1H-Pyrazole-3-methanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-56-4 CAPLUS


CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-57-5 CAPLUS

CN 1H-Pyrazole-3-propanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-59-7 CAPLUS

CN 4-Quinazolinamine, N-[5-(3-methoxypropyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404828-60-0 CAPLUS

CN 4-Quinazolinamine, N-[5-(3-aminopropyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404828-62-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-63-3 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 404828-64-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-methoxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-65-5 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(phenylmethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-66-6 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-cyclohexyl-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-67-7 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N,N-diethyl-5-[(2-phenyl-4-quinazolinyl)amino]-
(9CI) (CA INDEX NAME)


RN 404828-68-8 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-phenylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-69-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-propyl-
(9CI) (CA INDEX NAME)




RN 404828-70-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-ethyl-N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-71-3 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-cyclopropyl-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-72-4 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(2-methylpropyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-73-5 CAPLUS


CN Pyrrolidine, 3-(methoxymethyl)-1-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 404828-74-6 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(3-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-75-7 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(4-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-76-8 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-methyl-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-77-9 CAPLUS

CN Morpholine, 4-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404828-78-0 CAPLUS

CN Piperazine, 1-methyl-4-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404828-79-1 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-hydroxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-80-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-82-6 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-83-7 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI)
(CA INDEX NAME)


ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

09/624,800

Thomas McKenzie

RN 404828-84-8 CAPLUS


CN 1H-Pyrazole-4-carbonitrile, 3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-85-9 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-morpholinyl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-86-0 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-piperazinyl)- (9CI)
(CA INDEX NAME)